Surgical microwave ablation of 397 neuroendocrine liver metastases: a retrospective cohort analysis of 16 years of experience.
Debulking
Liver metastasis
Microwave ablation
Neuroendocrine tumor
Journal
Surgical endoscopy
ISSN: 1432-2218
Titre abrégé: Surg Endosc
Pays: Germany
ID NLM: 8806653
Informations de publication
Date de publication:
09 Oct 2024
09 Oct 2024
Historique:
received:
06
03
2024
accepted:
30
06
2024
medline:
10
10
2024
pubmed:
10
10
2024
entrez:
9
10
2024
Statut:
aheadofprint
Résumé
Neuroendocrine tumors (NET) constitute a heterogeneous group of malignancies whose incidence has been on the rise over the past two decades, currently documented at 5.25 per 100,000. Liver metastasis develops in over 60% of NET patients. Even after resection recurrence rates are high, underscoring the importance of parenchymal-sparing interventions. In this study, we conducted 105 surgical microwave ablations and examined outcomes related to survival and local recurrence. Retrospective review of patients who underwent a surgical microwave ablation (MWA) at a single-center, high-volume institution from September 2007 through December 2022 using a prospective database. Primary outcome was overall survival. A total of 105 operations were performed on 94 patients, with 397 tumors undergoing MWA. Median tumor size was 1.3 cm (range 0.3-8.0), and the median number of tumors ablated was 2 (range 1-12). Laparoscopic approach was utilized 69.5% of the time. The most common concomitant procedure performed was hepatectomy (33.3%) and cholecystectomy (23.8%). Clavien-Dindo grade III or IV complications occurred in 9 patients (9.6%). Mortality within 30 days occurred in 1 patient (1.1%). The rate of incomplete ablation was 0.3% per tumor. Local recurrence occurred in 2.8% of tumors. Median OS was 9.43 years [95% CI 4.23-14.63 years], with a 5- and 10-year survival probability of 70.2% and 48.2%, respectively. Surgical MWA offers an efficacious, parenchymal-sparing treatment of hepatic metastasis of NET, with low rates of incomplete ablation and local recurrence per tumor.
Sections du résumé
BACKGROUND
BACKGROUND
Neuroendocrine tumors (NET) constitute a heterogeneous group of malignancies whose incidence has been on the rise over the past two decades, currently documented at 5.25 per 100,000. Liver metastasis develops in over 60% of NET patients. Even after resection recurrence rates are high, underscoring the importance of parenchymal-sparing interventions. In this study, we conducted 105 surgical microwave ablations and examined outcomes related to survival and local recurrence.
METHODS
METHODS
Retrospective review of patients who underwent a surgical microwave ablation (MWA) at a single-center, high-volume institution from September 2007 through December 2022 using a prospective database. Primary outcome was overall survival.
RESULTS
RESULTS
A total of 105 operations were performed on 94 patients, with 397 tumors undergoing MWA. Median tumor size was 1.3 cm (range 0.3-8.0), and the median number of tumors ablated was 2 (range 1-12). Laparoscopic approach was utilized 69.5% of the time. The most common concomitant procedure performed was hepatectomy (33.3%) and cholecystectomy (23.8%). Clavien-Dindo grade III or IV complications occurred in 9 patients (9.6%). Mortality within 30 days occurred in 1 patient (1.1%). The rate of incomplete ablation was 0.3% per tumor. Local recurrence occurred in 2.8% of tumors. Median OS was 9.43 years [95% CI 4.23-14.63 years], with a 5- and 10-year survival probability of 70.2% and 48.2%, respectively.
CONCLUSION
CONCLUSIONS
Surgical MWA offers an efficacious, parenchymal-sparing treatment of hepatic metastasis of NET, with low rates of incomplete ablation and local recurrence per tumor.
Identifiants
pubmed: 39384658
doi: 10.1007/s00464-024-11021-4
pii: 10.1007/s00464-024-11021-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Gangi A, Howe JR (2020) The landmark series: neuroendocrine tumor liver metastases. Ann Surg Oncol 27:3270–3280
doi: 10.1245/s10434-020-08787-x
pubmed: 32632880
pmcid: 7415723
Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB (2008) One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26:3063–3072
doi: 10.1200/JCO.2007.15.4377
pubmed: 18565894
Riihimaki M, Hemminki A, Sundquist K, Sundquist J, Hemminki K (2016) The epidemiology of metastases in neuroendocrine tumors. Int J Cancer 139:2679–2686
doi: 10.1002/ijc.30400
pubmed: 27553864
Hallet J, Law CH, Cukier M, Saskin R, Liu N, Singh S (2015) Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer 121:589–597
doi: 10.1002/cncr.29099
pubmed: 25312765
Maire F, Hammel P, Kianmanesh R, Hentic O, Couvelard A, Rebours V, Zappa M, Raymond E, Sauvanet A, Louvet C, Lévy P, Belghiti J, Ruszniewski P (2009) Is adjuvant therapy with streptozotocin and 5-fluorouracil useful after resection of liver metastases from digestive endocrine tumors? Surgery 145:69–75
doi: 10.1016/j.surg.2008.08.007
pubmed: 19081477
Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M, Harder J, Arnold C, Gress T, Arnold R (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 27:4656–4663
doi: 10.1200/JCO.2009.22.8510
pubmed: 19704057
Yao JC, Phan AT, Chang DZ, Wolff RA, Hess K, Gupta S, Jacobs C, Mares JE, Landgraf AN, Rashid A, Meric-Bernstam F (2008) Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 26:4311–4318
doi: 10.1200/JCO.2008.16.7858
pubmed: 18779618
pmcid: 2653122
di Bartolomeo M, Bajetta E, Buzzoni R, Mariani L, Carnaghi C, Somma L, Zilembo N, di Leo A (1996) Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer 77:402–408
doi: 10.1002/(SICI)1097-0142(19960115)77:2<402::AID-CNCR25>3.0.CO;2-4
pubmed: 8625251
Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG (2003) Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 197:29–37
doi: 10.1016/S1072-7515(03)00230-8
pubmed: 12831921
Sarmiento JM, Que FG (2003) Hepatic surgery for metastases from neuroendocrine tumors. Surg Oncol Clin N Am 12:231–242
doi: 10.1016/S1055-3207(02)00076-5
pubmed: 12735141
Izzo F, Granata V, Grassi R, Fusco R, Palaia R, Delrio P, Carrafiello G, Azoulay D, Petrillo A, Curley SA (2019) Radiofrequency ablation and microwave ablation in liver tumors: an update. Oncologist 24:e990–e1005
doi: 10.1634/theoncologist.2018-0337
pubmed: 31217342
pmcid: 6795153
Byrd JF, Agee N, McKillop IH, Sindram D, Martinie JB, Iannitti DA (2011) Colour doppler ultrasonography provides real-time microwave field visualisation in an ex vivo porcine model. HPB (Oxford) 13:400–403
doi: 10.1111/j.1477-2574.2011.00302.x
pubmed: 21609372
Berber E, Flesher N, Siperstein AE (2002) Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. World J Surg 26:985–990
doi: 10.1007/s00268-002-6629-5
pubmed: 12016479
Kose E, Kahramangil B, Aydin H, Donmez M, Takahashi H, Aucejo F, Siperstein A, Berber E (2020) Outcomes of laparoscopic tumor ablation for neuroendocrine liver metastases: a 20-year experience. Surg Endosc 34:249–256
doi: 10.1007/s00464-019-06759-1
pubmed: 30945061
Saxena A, Chua TC, Sarkar A, Chu F, Liauw W, Zhao J, Morris DL (2011) Progression and survival results after radical hepatic metastasectomy of indolent advanced neuroendocrine neoplasms (NENs) supports an aggressive surgical approach. Surgery 149:209–220
doi: 10.1016/j.surg.2010.06.008
pubmed: 20674950
Mayo SC, de Jong MC, Pulitano C, Clary BM, Reddy SK, Gamblin TC, Celinksi SA, Kooby DA, Staley CA, Stokes JB, Chu CK, Ferrero A, Schulick RD, Choti MA, Mentha G, Strub J, Bauer TW, Adams RB, Aldrighetti L, Capussotti L, Pawlik TM (2010) Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol 17:3129–3136
doi: 10.1245/s10434-010-1154-5
pubmed: 20585879
Bagante F, Spolverato G, Merath K, Postlewait LM, Poultsides GA, Mullen MG, Bauer TW, Fields RC, Lamelas J, Marques HP, Aldrighetti L, Tran T, Maithel SK, Pawlik TM (2017) Neuroendocrine liver metastasis: the chance to be cured after liver surgery. J Surg Oncol 115:687–695
doi: 10.1002/jso.24563
pubmed: 28146608
Lee FT, Williams J, Nordgren R, Schwarz JL, Setia N, Roggin K, Polite B, Rangrass G, Liao CY, Millis JM, Keutgen XM (2024) Single center outcomes from parenchymal-sparing resections and microwave ablations for neuroendocrine tumor liver metastases. Am J Surg 229:17–23
doi: 10.1016/j.amjsurg.2023.09.020
pubmed: 37802701
Glazer ES, Tseng JF, Al-Refaie W, Solorzano CC, Liu P, Willborn KA, Abdalla EK, Vauthey JN, Curley SA (2010) Long-term survival after surgical management of neuroendocrine hepatic metastases. HPB (Oxford) 12:427–433
doi: 10.1111/j.1477-2574.2010.00198.x
pubmed: 20662794
Curley SA, Izzo F, Ellis LM, Nicolas Vauthey J, Vallone P (2000) Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis. Ann Surg 232:381–391
doi: 10.1097/00000658-200009000-00010
pubmed: 10973388
pmcid: 1421151
Saxena A, Chua TC, Perera M, Chu F, Morris DL (2012) Surgical resection of hepatic metastases from neuroendocrine neoplasms: a systematic review. Surg Oncol 21:e131-141
doi: 10.1016/j.suronc.2012.05.001
pubmed: 22658833
Cipriani F, Ratti F, Cardella A, Catena M, Paganelli M, Aldrighetti L (2019) Laparoscopic versus open major hepatectomy: analysis of clinical outcomes and cost effectiveness in a high-volume center. J Gastrointest Surg 23:2163–2173
doi: 10.1007/s11605-019-04112-4
pubmed: 30719675
Cannon RM, Scoggins CR, Callender GG, Quillo A, McMasters KM, Martin RC 2nd (2013) Financial comparison of laparoscopic versus open hepatic resection using deviation-based cost modeling. Ann Surg Oncol 20:2887–2892
doi: 10.1245/s10434-013-2993-7
pubmed: 23636514
Tinguely P, Laurell G, Enander A, Engstrand J, Freedman J (2023) Ablation versus resection for resectable colorectal liver metastases—health care related cost and survival analyses from a quasi-randomised study. Eur J Surg Oncol 49:416–425
doi: 10.1016/j.ejso.2022.09.006
pubmed: 36123245